One of the presenters at the JPMorgan conference yesterday was the biotech Dendreon (NASDAQ: DNDN), a stock that gets a lot of attention from readers of Fool.com. In this video, Motley Fool health care bureau chief Brenton Flynn discusses three bullish points from the company's presentation. He gives us areas where the company is growing, tells us how it is increasing awareness around its treatment -- which may buoy all players in that sector -- and talks about some progress that the company has made in its restructuring efforts.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
3 Bullish Signs From a Struggling Biotech
A bull's view of Dendreon's conference presentation.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.